News

Virometix AG Announces Positive Data from Phase 1 Trial of V-212, a Fully Synthetic, Serotype-Independent Vaccine Development Candidate for the Prevention of Pneumococcal Disease

SCHLIEREN, Switzerland--(BUSINESS WIRE)--Virometix AG, a clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced positive topline data from the Company’s Phase 1 trial of its lead asset V-212, a serotype-independent pneumococcal vaccine candidate, in development for the prevention of pneumococcal disease caused by Streptococcus pneumoniae (Spn) infections. The study evaluated safety and...

read more

hemotune AG appoints a new Chief Business Officer

At the interface of MedTech and Pharma, hemotune AG is engineering a world‑leading magnetic nanoparticle platform to transform separation across the medical value chain – and beyond. 📢 Today, we are delighted to announce that Christian Brühlmann has joined hemotune as Chief Business Officer. With this appointment, our C‑level expands to...

read more

ImmunOs Therapeutics Appoints Dr. Hilmar Ebersbach as Chief Executive Officer

Schlieren, Switzerland, January 5, 2026- ImmunOs Therapeutics AG is pleased to announce that Hilmar Ebersbach, former Chief Scientific Officer of the Company, has been nominated as Chief Executive Officer, effective January 2026. Hilmar brings deep scientific expertise, a strong track record in drug discovery including translational development as well as...

read more

KUORI Enters B2C with Filament Built for Next-Gen Makers

Zurich, Switzerland – 05. December 2025 A game changer for the next generation of circular makers: Swiss cleantech startup KUORI is shaking up the world of material and product design with the launch of a 3D printing filament based on its flagship material BIOWA, a bio-based, biodegradable and recyclable thermoplastic...

read more